<code id='887CBAF81F'></code><style id='887CBAF81F'></style>
    • <acronym id='887CBAF81F'></acronym>
      <center id='887CBAF81F'><center id='887CBAF81F'><tfoot id='887CBAF81F'></tfoot></center><abbr id='887CBAF81F'><dir id='887CBAF81F'><tfoot id='887CBAF81F'></tfoot><noframes id='887CBAF81F'>

    • <optgroup id='887CBAF81F'><strike id='887CBAF81F'><sup id='887CBAF81F'></sup></strike><code id='887CBAF81F'></code></optgroup>
        1. <b id='887CBAF81F'><label id='887CBAF81F'><select id='887CBAF81F'><dt id='887CBAF81F'><span id='887CBAF81F'></span></dt></select></label></b><u id='887CBAF81F'></u>
          <i id='887CBAF81F'><strike id='887CBAF81F'><tt id='887CBAF81F'><pre id='887CBAF81F'></pre></tt></strike></i>

          fashion

          fashion

          author:focus    Page View:1
          In the center, three researchers examine a DNA helix. Two people stand in the front, one puts an apple into a capsule containing vegetables, the other holds a check list while standing next to a pile of medicines. On the right side, a scientist injects into mitochondria while another takes notes. A person behind the duo looks at a projection of a brain. On the left side, a client looks at a heart projection from a device held by a robot — biotech coverage from STAT
          Adobe

          When it comes to bringing an experimental drug to market and selling it, Novo Nordisk, the maker of the weight loss drug Wegovy, is tops, according to a new analysis.

          But if you want to invent lots of potential drugs that could eventually reach the market, you’d be far better off with Johnson & Johnson, Merck, or AstraZeneca.

          advertisement

          The analysis, the 13th edition of the Pharmaceutical Innovation and Invention Index, was produced by the consultancy Idea Pharma and released Thursday at the STAT Breakthrough Summit in San Francisco.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the pharma industry — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          Medicare details structure of new drug price negotiation program
          Medicare details structure of new drug price negotiation program

          MedicareonFridayreleasednewdetailsabouthowitsnewdrugpricenegotiationprogramwillwork,justtwomonthsbef

          read more
          Takeda, Janssen join wearable maker to measure scratching
          Takeda, Janssen join wearable maker to measure scratching

          AdobeYou’rereadingthewebeditionofSTAT’sHealthTechnewsletter,ourguidetohowtechnologyistransformingthe

          read more
          Hepatitis C has a cure — but many Americans still lack access to it
          Hepatitis C has a cure — but many Americans still lack access to it

          AdobeIn2005,NickVoyleswasdiagnosedwithhepatitisCafterbeingreleasedfromfiveyearsofincarceration.Anurs

          read more

          Russian fighter jet damages US Reaper drone with flare over Syria: Officials

          0:42ARussianfighterfliesdangerouslyclosetoaU.S.MQ-9beforedeployingflaresfromapositiondirectlyoveranM